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A B S T R A C T
Background: The International Restless Legs Scale (IRLS) is the most widely used of the scales rating the
severity of restless legs syndrome/Willis–Ekbom disease (RLS/WED). It has been well validated and is
the primary end point for most of the therapeutic and nontherapeutic studies of RLS/WED. It has ex-
cellent psychometric properties, although it does not capture the severity of RLS under a wide variety
of circumstances and times of day. Moreover, the IRLS has a large placebo effect.
Methods: The Restless Legs Syndrome-6 Scale (RLS-6), however, takes another potentially valuable ap-
proach. Six items are rated on a 0–10 scale from no symptoms at 0 to very severe at 10. In addition to
questions on satisfaction with sleep and sleepiness, the scale rates the severity of RLS for the past week
under four separate circumstances: while falling asleep, during the night, during the day while sitting
or lying, and during the day when moving around. The purpose of the current study is to report the val-
idation of the RLS-6 under baseline and therapeutic conditions.
Results: The RLS-6 seems to be an acceptable, reliable, precise, valid, and responsive instrument for the
assessment of RLS severity in a speciﬁc and pragmatic manner.
Conclusions: At present, we view the RLS-6 not as a replacement for the IRLS but as a supplement, as
each scale provides information not captured by the other.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
For the evaluation of restless legs syndrome/Willis–Ekbomdisease
(RLS/WED) severity, three scales have been developed and used in
clinical and trial practice: the International Restless Legs Scale (IRLS),
the Johns Hopkins Restless Legs Severity Scale (JHRLSS), and the
Restless Legs Syndrome-6 Scale (RLS-6). The validations of the IRLS
and the JHRLSS have been published [1–6], but the validation of
the third, the RLS-6, has only been previously published in ab-
stract form [7].
The IRLS is the most widely used of the three scales, has been
translated in to multiple languages, and is the major end point for
the rating of RLS/WED severity in most academic and pharmaceu-
tical company studies of RLS/WED. It captures a general impression
of overall severity, the severity of arm and leg discomfort, the se-
verity of the need tomove, the relief obtained by activity, the number
of hours a day and the number of days per week with symptoms,
the severity of sleep disturbance and tiredness/sleepiness, as well
as the impact of RLS symptoms onmood and quality of life. However,
as opposed to the RLS-6, the IRLS does not capture the severity of
symptoms during the night or while falling asleep versus the day
while at rest or, alternatively, when moving around. As opposed to
the JHRLSS, the IRLS also does not determine the severity of RLS
as determined by the time of day of usual onset of symptoms [6].
Thus, all three of these scales provide useful, important but differ-
ent measures of RLS severity. In addition, the RLS-6 has been used
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in multiple clinical trials as an accessory secondary end point
together with the IRLS, which has been generally used as the primary
end point. Moreover, the IRLS has a large placebo effect [8].
The aim of this study was to validate the RLS-6 according to the
classical test theory. The RLS-6 is currently the only scale that has
been used to speciﬁcally rate the severity of daytime versus night-
time symptoms in RLS; as such, it has been used in many studies
and clinical trials, especially those that focus on the daytime symp-
toms of RLS, independent of the sleep disturbances [9–14].
2. Methods
2.1. Patients
The sample considered for the present study was selected from
four multicenter, double-blind, randomized active or placebo-
controlled clinical trials [9–14].
The inclusion criteria for these studies were as follows: male and
female patients aged 18–75 years (cabergoline (CBG) trials: CALDIR,
CABAS-0067-031: CT.gov Identiﬁer: NCT00625547; CATOR, CABAS-
0067-033: CT.gov Identiﬁer: NCT00627003) or 18–80 years (lisuride
trials: TULIR 02/01, EudraCT Number: 2004-001589-42; TULIR 03/
01, EudraCT Number: 2005–003549-16), with all four clinical
manifestations of RLS according to the IRLSSG criteria [15]. The se-
verity of symptoms had to be at least moderate according to the
IRLS total score at baseline (≥10 for CBG trials; ≥ 15 for lisuride trials),
and a “severity at night” score of ≥4 (CBG trials) in the RLS-6 rating
scale. Patients were either de novo or unsatisﬁed with previous RLS
therapy.
The patients included in the responsiveness analyses (n = 261)
comprised 69.73% of women aged (mean ± standard deviation (SD))
60.94 ± 10.34 years. The age at RLS onset was 46.63 ± 16.45 years
and the RLS duration 14.31 ± 13.97 years. The patients were receiv-
ing treatment for RLS for 3.25 ± 2.87 years. The IRLS total score was
28.64 ± 5.94 (range: 15–38), and the Epworth Sleepiness Scale (ESS)
score was 8.06 ± 5.23 (0–21). Most of these patients had markedly
severe RLS (39.85%), followed by moderate or severe disorder (each
level 27.60%), as per the Clinical Global Impression of Severity (CGIS).
The exclusion criteria were as follows: 1) Patients with second-
ary RLS, iron deﬁciency, or other clinically relevant concomitant
diseases, relevant ﬁndings in ancillary tests, and skin disorders on
the application area (lisuride patch trials) [11,12], although uremic
RLS patients were allowed in the TULIR03 study (lisuride); 2) pa-
tients with established or suspected hypersensitivity to the tested
drug or with nonresponse intolerability to previous CBG or L-dopa
therapy [9,10]; 3) concomitant use of drugs with a probable inﬂu-
ence on RLS or sleep structure, which had to be discontinued at the
start of the washout period 1 week before baseline; and 4) pa-
tients previously treated with CBG [9] or the drug had to
discontinued two months before screening [10]. Women of child-
bearing potential had to use a reliable method of contraception.
Patients were recruited in the outpatient unit of neurological hos-
pitals or in private neurological sleep laboratories.
2.2. Ethical issues
All four studies were approved by the corresponding ethics com-
mittees and patients signed the informed consent forms before
inclusion in the study.
2.3. Assessments
In addition to the RLS-6 [7], the following assessments were
applied: IRLS, version for clinical trials [16]; ESS [17]; and CGIS [18].
The RLS-6 is composed of six items scoring on a 0–10 scale from
no symptom at 0 to very severe at 10. In addition to questions on
satisfaction with sleep and sleepiness, the scales rate the severity
of RLS for the past week under four separate circumstances, while
falling asleep, during the night, during the day while sitting or lying,
and during the day when moving around (Table 1). Thus, the se-
verity of RLS under different circumstances and times of day would
potentially be captured better with the RLS-6 than with previous
RLS severity instruments. The RLS-6 scale was not designed to cal-
culate a total score, but it assesses some speciﬁc domains: (1) Sleep
quality (items 1 and 6); (2) RLS at Nighttime (items 2 and 3); (3)
Daytime RLS manifestations during relaxation (item 4); and (4) RLS
during activity (which mainly refers to RLS mimics) (item 5), which
is actually a control question to differentiate RLS from other disorders.
The IRLS consists of 10 questions rated from 0 to 4. In addition
to the total score, two sub-scores can be obtained: severity and life
impact. The scale is applied during a face-to-face interviewwith the
patient where any clariﬁcations regarding the questions can bemade
to the patient. It is the most extensively used of the RLS severity
scales in research studies of all types. It has excellent clinimetric
Table 1
RLS-6 rating scales.
Please, evaluate the following questions for the last 7 days or nights respectively:
How satisﬁed are you with your sleep during the last 7 nights?
completely satisﬁed completely dissatisﬁed
0 1 2 3 4 5 6 7 8 9 10
How severe were your RLS symptoms during the last 7 nights or days respectively in the following situations?
At falling asleep
none very mild very severe
0 1 2 3 4 5 6 7 8 9 10
During the night
none very mild very severe
0 1 2 3 4 5 6 7 8 9 10
During the day when you were at rest (sitting, lying)
none very mild very severe
0 1 2 3 4 5 6 7 8 9 10
During the day when you were not at rest but engaged in activities (walking, activities in your job, homework, leisure activities)
none very mild very severe
0 1 2 S 4 5 6 7 8 9 10
How tired or sleepy were you during the day (between getting up in the morning and bedtime in the evening) within the last 7 days?
not at all very mild very severe
0 1 2 3 4 5 6 7 8 9 10
The RLS-6 is the result of a joint work undertaken by EURLSSG members. The EURLSSG owns intellectual property over the RLS-6 including but not limited to all and any
translations and other derivatives (e.g. electronic versions). The EURLSSG has assigned Mapi Research Trust for the management of the instrument licenses and permission
to use. Please consult the Mapi Research Trust website: http://www.proqolid.org.
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properties and is used as the benchmark outcomemeasure for treat-
ment trials in RLS.
The ESS is an eight-item scale to assess excessive daytime som-
nolence and has been frequently used in Parkinson’s disease. The
CGIS provides a score from 0 (not assessed) to 7 (among the most
extremely ill patients).
2.4. Data analysis
A database for the present study was created from the previ-
ouslymentioned studies [9–14] and submitted to the National Center
of Epidemiology (ISCIII, Madrid, Spain). Descriptive statistics (central
tendency and dispersion, and proportions) were applied to the vari-
ables in the study to characterize the sample.
The main variables in the study were not normally distributed
(graph plot or the Kolmogorov–Smirnov test); therefore, nonpara-
metric statistics were used. The following clinimetric attributes were
determined and tested against the corresponding standard values:
Acceptability: This included attributes such as percentage of
missing data (standard <10%) [19], mean and median closeness (ar-
bitrary limit for the difference: 10% of the maximum theoretical
score) [20,21], range of scores (standard: the complete theoretical
range of scores) [22], skewness (between −1 and +1) [22], and the
ﬂoor-and-ceiling effect (<15%) [23].
Dimensionality: This was explored by factor analysis and prin-
cipal component analysis. The number of factors was chosen
according to the Kaiser criterion (eigenvalue > 1) and scree plot in-
spection. The Bartlett sphericity index for suitability of the analysis
(p < 0.05) and the Kaiser–Meyer–Olkin measure for sampling ade-
quacy (>0.60) were considered [24].
Internal consistency: Cronbach’s alpha index, as a reliability index
(standard, >0.70) [25], and item homogeneity index (standard >0.40)
[26] were determined, excluding item 5.
As all patients in the several studies providing the sample re-
ceived treatment after the baseline assessment, it was not possible
to ﬁnd a stable group according to IRLS scores. Therefore, test–
retest was not explored.
Hypotheses testing: A close association (r ≥ 0.60) was expected
between the RLS-6 and IRLS corresponding scores, whereas mod-
erate (r = 0.40–0.59) or low correlations (r ≤ 0.39) were hypothesized
between other components of both scales. A moderate associa-
tion was foreseen between RLS-6 domains and CGIS. Moderate to
low correlations were expected with other variables in the study.
The limits for internal validity were deemed satisfactory if the inter-
domain correlation was between 0.30 and 0.70 [19]. The known-
group validity was determined for gender and categories of age,
severity of RLS based on the IRLS scores, CGIS, and duration of the
RLS. A signiﬁcant increase of the RLS-6 scores was expected with
increasing IRLS score-based and CGIS grades, whereas the relation-
ship with the other variables would be weak or nonsigniﬁcant. For
the continuous variables, grouping was performed according to the
median and interquartile range. Comparisons were analyzed with
the Mann–Whitney and Kruskal–Wallis tests, and the Bonferroni
correction for multiple comparisons was applied.
Responsiveness: This was deﬁned as the ability of the RLS-6 to
detect a change; for comparison, the IRLS was also analyzed. For
these analyses, we chose a group of patients receiving placebo
(n = 82) and a group receiving lisuride (n = 179) from two clinical
trials with lisuride. They were selected because of their homoge-
neous follow-up period (90 ± 7 days). The remaining patients in the
trials on which this study is based varied widely in their follow-
up periods and were therefore not appropriate for this kind of
analysis. At baseline, there was no statistical difference between the
placebo and lisuride arms for age, gender, age at onset, and RLS du-
ration. A signiﬁcant intra-group improvement was observed at
follow-up (90 ± 7 days) in both groups, although it was higher for
the treated arm (except for the item 5). Relative change [27], effect
size, standardized response mean, coeﬃcient of responsiveness
([Mean (test1 − test2)treatment − Mean (test1 − test2)control]/SDtest1 pooled),
and correlation of change between RLS-6 and IRLS were calcu-
lated [28,29].
3. Results
A total of 892 patients, with 71.5% females and of age (mean ± SD)
58.73 ± 11.47 years were included in the study. The descriptive data
of the sample are shown in Table 2. There were no missing data.
The central tendency and dispersion data of the RLS-6 are dis-
played in Table 3, together with the parameters of acceptability. The
following observations are worth noting: all RLS-6 items and scores
Table 2
Descriptive data of the sample and scales.
Mean SD Min. Max.
Body mass index 26.53 4.10 16.90 44.98
RLS duration 13.36 13.19 0 59.70
Duration of treatment (a) 2.69 2.95 0 21.93
Age at onset (b) 45.37 16.19 3.63 78.68
IRLS Total score 27.49 6.31 10 40
IRLS Sub-score severity 19.46 3.88 6 24
IRLS Sub-score impact 6.37 3.04 0 12
Clinical Global Impression 4.83 0.94 1 7
Epworth Sleepiness Scale 7.85 4.95 0 22
N = 892, except (a) n = 704 and (b) n = 891.
SD: standard deviation. Min.: Minimum. Max.: Maximum.
IRLS: International Restless Legs Scale.
Table 3
Acceptability parameters of the RLS-6.
RLS-6 items Mean (SD) Median Minim Maxim. Skewness Floor effect Ceiling effect
1. Satisﬁed with sleep 7.17 (2.42) 8 0 10 −0.63 1.01 23.52
2. RLS symptoms at falling asleep 6.09 (3.00) 7 0 10 −0.39 5.04 17.47
3. RLS symptoms during the night 6.74 (2.60) 7 0 10 −0.58 1.57 18.25
4. RLS symptoms during the day at rest 4.91 (2.62) 5 0 10 −0.08 6.38 3.92
5. 4. RLS symptoms during activities in the day 1.59 (2.06) 1 0 10 1.45 45.35 0.34
6. Tired or sleepy during the day 5.09 (2.78) 5 0 10 0.10 3.58 8.96
RLS-6 domains
1. Sleep quality (items 1 + 6) 12.26 (4.35) 12 0 20 −0.05 0.11 7.17
2. RLS Nighttime (items 2 + 3) 12.83 (4.79) 13 1 20 −0.19 0.11 11.87
3. Daytime RLS (item 4) 4.91 (2.62) 5 0 10 −0.08 6.38 3.92
4. RLS Mimics (item 5) 1.59 (2.06) 1 0 10 1.45 45.35 0.34
N = 892.
RLS-6: Restless Legs Scale – six items.
SD: Standard deviation. Minim.: Minimum. Maxim.: Maximum.
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covered the possible range of scoring (0–10 for individual items as
well as 1–20 for domains 1 and 2); the mean–median difference was
lower than one point (≤10%) for all RLS-6 values; only one value (item
5) was marginally out of the acceptable range (−1 to +1) for skew-
ness; and a mild ceiling effect was noted in items 1, 2, and 3, and a
moderate ﬂoor effect in item 5, but items 4 and 6 and the total score
of domains 1 (Sleep quality) and 2 (RLS at nighttime) were free of
both effects (Table 3).
The factor analysis (item 5 excluded) showed only one factor ex-
plaining 55% of the variance (eigenvalue: 2.77; loadings: 0.64–
0.83 in orthogonal rotations; Bartlett test, p < 0.001; Kaiser–Meyer–
Olkin test, 0.77). In terms of the internal consistency (item 5
excluded), Cronbach’s alpha was 0.79; the item-total correlation
ranged from 0.47 (item 6) to 0.68 (item 1); and the inter-item cor-
relation ranged from 0.36 (item 3 to item 6) to 0.75 (item 1 to item
3), with an item homogeneity index of 0.46.
The correlation coeﬃcients of the RLS-6 items ranged from 0.08
to 0.76 (mean: 0.40) with the IRLS items and from 0.35 to 0.67 with
the IRLS total score (Table 4). The correlations between RLS-6 and
IRLS sub-scores of severity and impact were high to moderate
(Table 5). Overall, the correlation coeﬃcients from domains 3
(Daytime RLS manifestations) and 4 (Possible RLS mimics) indi-
catedmoderate or weak associations; the association between RLS-6
domains and CGIS was moderate or weak; and a negligible asso-
ciation was noted between the RLS-6 and ESS (Table 5). The latter
two ﬁndings were similar to the correlations ESS–IRLS (rS = 0.06;
p = 0.08) and ESS–CGIS (rS = 0.03; p = 0.31). Finally, the RLS-6 scores
showed negligible correlation with age, body mass index, and RLS
duration (all, rS ≤ 0.16), and a weak relationship with the duration
of treatment for RLS (N = 702; RLS-6 domains 1–3, rS = 0.19–0.23;
p < 0.0001).
The inter-domain correlations (internal validity) between domains
1 and 3 ranged from 0.44 to 0.67. Domain 4 (Possible RLS mimics)
showed a coeﬃcient of 0.46 with domain 3 (Daytime RLS mani-
festations during relaxation), and a correlation lower than 0.30 with
the other two. In terms of the known-group validity, the RLS-6 scores
did not differ signiﬁcantly by gender, age, or RLS duration catego-
ries as a whole, and they were signiﬁcantly correlated with the RLS
severity determined by the IRLS and CGIS categories (Table 6).
The relative change, effect size, and standardized response mean
for each arm of the clinical trial and scale are shown in Table 7. These
parameters were sensitive to both the placebo and lisuride effect,
although all of themwere higher in the active treatment group. The
RLS-6 domain 4 (Possible RLS mimics) showed the lowest effect size
and standardized response mean of all RLS-6 dimensions, and the
differences between the placebo and treated arms were minimal
(in the centesimal order). The coeﬃcient of responsiveness between
arms was 0.01–0.49 for the RLS-6 components and 0.83 for the IRLS
(Table 7).
In the placebo arm, the correlation between the change in the
RLS-6 subscales and that in the IRLS total score was 0.67 for RLS-6
domain 1 (Sleep quality), 0.70 for domain 2 (RLS at nighttime), 0.62
for domain 3 (Daytime RLS), and 0.20 for domain 4 (RLS mimics).
In the lisuride arm, the values were 0.72, 0.82, 0.70, and 0.33,
respectively.
4. Discussion
The analysis of the clinimetric properties of RLS-6 was carried
out on data of a wide and representative sample of patients from
four clinical trials including broad ranges of age, age at onset, du-
ration of disease, and severity of the RLS manifestations. This study
was preceded by analyses of some clinimetric properties of RLS-6
in 299 patients from an interim analysis of the two clinical trials
with CBG contributing to the data set of the present study [7,9,10],
For most of the results, the values were close to those of the present
study.
In the early evaluation study of RLS-6 by Professor Ralf Kohnen,
item5was analyzed jointlywith item4 [7].However, there are several
arguments for analyzing item 5 separately from the other items in
the current analysis. First, conceptually, item 5 was included in the
scale to discriminate RLS from non-RLS symptoms rather than as-
sessing the severity of RLS. True RLS would not be expected to be
more severe during activities such aswalking. Second, this itemwas
combinedwith item 4 in the early evaluation study by Prof Kohnen
to evaluate symptomsduring thedaytime,whichwas initially correct.
However, at present,we consider itmore pragmatic to separate these
two items, reserving item 4 for evaluating genuine RLS symptoms
during the daytime. Third, the ﬁndings of the validation analysis
favor the decision of leaving item 5 apart. It was the only item
with out-of-the-limit skewness and moderate ﬂoor effect. After
excluding item 5, the scale is unidimensional, evaluating (only) RLS
severity. The convergent validity of this item/dimension with the
IRLS was, overall, the lowest, and it also showed the lowest respon-
siveness (ES and SRM) to effective treatment. Therefore, the research
team decided to consider item 5 separately from item 4 in this ﬁrst
formal and wide validation study.
There were no missing data, which can be attributed to their
origin (monitored clinical trials). According to the IRLS and CGIS,
most of the patients showedmoderate or high severity of their symp-
toms with an IRLS score of 27.48 ± 6.34, which was reﬂected by the
total score of the RLS-6 items that reached their potential maximum
score. The RLS-6 domains showed negligible skewness and ﬂoor-
and-ceiling effects [22,23]. They also cover their complete theoretical
range of scores (Table 3), in spite of the restriction imposed by the
inclusion criteria of the original studies (IRLS total score ≥ 10 for CBG
trials and ≥15 for lisuride trials). The apparent discrepancy between
Table 4
Convergent validity between RLS-6 and IRLS items and total score.
IRLS RLS-6
Item 1 Item 2 Item 3 Item 4 Item 5 Item 6
IRLS 1 0.61 0.51 0.62 0.45 0.22 0.36
IRLS 2 0.48 0.40 0.48 0.32 0.08a 0.27
IRLS 3 0.11b 0.08a 0.13 0.11 0.42 0.11
IRLS 4 0.69 0.50 0.66 0.30 0.15 0.35
IRLS 5 0.40 0.36 0.37 0.30 0.20 0.76
IRLS 6 0.61 0.49 0.61 0.41 0.22 0.33
IRLS 7 0.37 0.35 0.35 0.31 0.16 0.16
IRLS 8 0.51 0.45 0.54 0.43 0.34 0.30
IRLS 9 0.42 0.37 0.40 0.39 0.31 0.51
IRLS 10 0.40 0.35 0.37 0.34 0.26 0.50
IRLS Total score 0.67 0.57 0.66 0.49 0.35 0.59
N = 892.
RLS-6: Restless Legs Scale – six items.
IRLS: International Restless Legs Scale.
(a) p < 0.05; (b) p < 0.01; the rest, p < 0.001.
Table 5
Convergent validity of the RLS-6 domains.
RLS-6 domains
1. Sleep
quality
2. RLS
Nighttime
3. Daytime
RLS
4. RLS
Mimics
IRLS – Total score 0.74 0.68 0.49 0.35
IRLS – Subscale severity 0.62 0.70 0.46 0.25
IRLS – Subscale impact 0.70 0.49 0.41 0.31
Clinical Global Impression
of severity
0.51 0.50 0.33 0.11
Epworth Sleepiness Scale 0.10 −0.08 −0.02 0.10
N = 892.
IRLS: International Restless Legs Scale.
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the scales must be related to their different structure and content
and to the consideration of scores from RLS-6 domains (parts) versus
the IRLS total score (all).
Domain 4 (Possible RLS mimics; item 5 of RLS-6) performed dif-
ferently, withmild skewness and amoderate ﬂoor effect, whichmust
be attributed to its particular nature. The RLS-6 acceptability, there-
fore, was considered satisfactory.
Interestingly, the exploratory factor analysis showed that RLS-6
was a unidimensional scale, with all items loading highly on the
same factor. Thus, the ﬁve items of the RLS-6 focused on evaluat-
ing the aspects of RLS severity are grouped around a unique
construct, the RLS. In the preliminary study, a two-factor solution
was found, although RLS-6 item 5 (RLS during activity) was in-
cluded as it may have been essential for the appearance of the
separate “day-time” factor identiﬁed [7]. The factor analysis results
of the present study are in line with the reliability indices tested,
showing overall satisfactory values of internal consistency, which
surpass the threshold values for Cronbach’s alpha and the homo-
geneity index [25,26]. The value of the latter (0.37) was coincident
with the preliminary validation study [7]. To summarize, both the
structure and internal consistency of the RLS-6 were suitable.
RLS-6 item 1 (satisfactionwith sleep) and 3 (severity of RLS symp-
toms during night) were closely associated with IRLS items 1
(discomfort in legs or arms), 4 (sleep disturbances due to RLS), and
6 (self-perceived RLS severity). However, item 6 of the RLS-6 was
also highly correlated with the IRLS item 5 (both assessing tired-
ness and sleepiness during the day) (Table 4). Most of the correlations
between items from both scales were moderate in magnitude, but
the total scores (including IRLS severity and impact sub-scores)
showed a strong or moderate correlation between scales, except for
RLS-6 domain 4 (Possible RLS mimics), which was weakly corre-
lated with the IRLS (Table 5). These results are close to those found
Table 6
Discriminative validity of the RLS-6.
Categories n Sleep quality RLS at nighttime Daytime RLS Possible mimics
Gender
Males 254 11.98 ± 4.34 12.46 ± 4.77 4.63 ± 2.60 1.56 ± 1.97
Females 638 12.37 ± 4.35 12.98 ± 4.80 5.02 ± 2.62 1.60 ± 2.09
pa – 0.34 0.15 0.06 0.76
Age categories*
<52 228 12.82 ± 4.37 12.92 ± 4.65 5.05 ± 2.60 1.79 ± 2.22
52–61 222 12.61 ± 4.49 13.07 ± 4.90 4.93 ± 2.73 1.82 ± 2.13
62–66 223 11.90 ± 4.37 12.63 ± 4.77 4.75 ± 2.65 1.22 ± 1.73
≥67 219 11.70 ± 4.01 12.0 ± 4.87 4.88 ± 2.51 1.52 ± 2.08
pb – 0.02 0.73 0.69 0.015
RLS duration (years)*
<3.3 222 11.82 ± 4.34 12.04 ± 4.66 4.78 ± 2.38 1.80 ± 2.12
3.30–8.86 223 12.37 ± 4.48 13.07 ± 4.70 5.06 ± 2.64 1.76 ± 2.05
8.87–19.77 223 12.22 ± 4.34 12.64 ± 4.79 4.78 ± 2.64 1.37 ± 1.90
≥ 19.78 224 12.63 ± 4.23 13.56 ± 4.91 5.00 ± 2.81 1.41 ± 2.13
pb – 0.33 0.006 0.49 0.01
IRLS score
0–10 3 4.33 ± 4.51 6.00 ± 4.24 1.67 ± 0.58 1.00 ± 0.00
11–20 133 7.56 ± 2.94 7.89 ± 3.27 3.06 ± 2.15 0.70 ± 1.22
21–30 435 11.17 ± 3.28 11.78 ± 4.10 4.44 ± 2.36 1.25 ± 1.69
31–40 321 15.75 ± 3.29 16.36 ± 3.46 6.33 ± 2.41 2.41 ± 2.47
p – 0.0001 0.0001 0.0001 0.0001
Clinical global
Impression 3 12.67 ± 3.51 9.33 ± 0.58 2.00 ± 3.46 0.00 ± 0.00
1 7 11.43 ± 4.86 11.43 ± 3.74 4.14 ± 2.67 0.43 ± 0.53
2 43 8.47 ± 4.57 8.86 ± 4.49 3.53 ± 2.59 1.53 ± 2.29
3 267 10.03 ± 3.54 10.39 ± 4.39 4.12 ± 2.34 1.37 ± 1.71
4 351 12.3 ± 3.9 12.9 ± 4.11 4.83 ± 2.50 1.42 ± 1.91
5 208 15.43 ± 3.50 16.30 ± 3.88 6.21 ± 2.56 2.11 ± 2.44
6 13 18.15 ± 1.99 19.08 ± 1.50 7.85 ± 1.82 3.23 ± 3.49
7 0 – – – –
pb – 0.0001 0.0001 0.0001 0.007
* Categories according to interquartile range. SD: Standard deviation.
(a) Mann–Whitney test; (b) Kruskal–Wallis test. Bonferroni correction: signiﬁcant if p < 0.0025.
RLS-6: Restless Legs Scale – six items.
IRLS: International Restless Legs Scale.
RLS: Restless Legs Syndrome.
Table 7
Responsiveness of the RLS-6.
Placebo (n = 82) Lisuride (n = 179) Coeﬃcient of
responsiveness
RLS-6 RC (%) Effect size SRM RC (%) Effect size SRM
Sleep quality −21.8 0.61 0.52 −37.6 1.13 0.80 0.49
Nighttime RLS −30.7 0.75 0.69 −47.6 1.36 0.92 0.48
Daytime RLS −28.7 0.54 0.47 −46.2 1.01 0.73 0.38
Possible mimics −40.3 0.30 0.31 −44.2 0.34 0.35 0.01
IRLS −25.3 1.10 0.73 −41.0 2.09 1.10 0.83
RLS-6: Restless Legs Scale – six items.
IRLS: International Restless Legs Scale, total score.
RC: Relative change. SRM: standardized response mean.
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in the early validation study [7] and are indicative of the signiﬁ-
cant association between RLS-6 and IRLS, the scale most commonly
used to evaluate the RLS. Such a degree of closeness was ex-
pected, as both scales are self-completed or informed by the patients
and were designed for the same objective, although their different
structures (in components and scoring method) could have given
rise to noticeable differences in their performance. However, CGIS
data have a different origin, which explains their correlation with
the RLS-6 at a lower level than the IRLS. The ESS was unrelated to
the RLS-6 in this study, as the RLS-6 did not assess daytime sleep-
iness in a single item or separate domain.
The distribution of the RLS-6 scores with respect to groups based
on such concepts as age, gender, RLS duration and severity showed
that only severity categories based on other measures in the study
(IRLS and CGIS) generated signiﬁcant differences among them, thus
conﬁrming the discriminative ability of the scale (Table 6). This per-
formance indicates that, in addition to evaluative ability, RLS-6 is
a potential discriminative instrument (able to distinguish, at a point
in time, between groups determined by speciﬁc characteristics or
an independent measure) [30]. In summary, the scale scores are con-
sistent with theoretically derived hypotheses regarding the
underlying construct it intends to measure.
The relative change in the responsiveness of the RLS-6was similar
to that observed for the IRLS. However, the effect size and stan-
dardized response mean were moderately higher for the IRLS. For
both parameters, values of 0.50–0.79 are indicative of a moderate
effect and ≥0.80 of a large effect [28,31–33]; some values were “large”
for the IRLS and “moderate” for RLS-6, revealing a lower sensitiv-
ity to change for the RLS-6. This discrepancy can be attributed to
the more complex structure of the IRLS (10 items, two factors) [2],
which can capture variation in aspects not included into the RLS-
6. This also explains the difference in the coeﬃcient of responsiveness
with both scales distinguishing the effect of the treatments (placebo
vs. lisuride). Overall, the effect size and standardized response mean
for the placebo arm were higher for the IRLS total score than for
the RLS-6 domains, whereas the relative change was similar. These
ﬁndings are in line with the meta-analysis of the placebo effect con-
ducted by Fulda et al. [8]. Nevertheless, themagnitude of the placebo
effect with differentmeasures is remarkable andmay be relatedmore
with RLS as a disorder assessed through purely subjective infer-
ences than with scale properties [5]. In the early validation study,
themaximum effect size of improvement was observed for the RLS-6
item “severity during the night,” [7] which is in line with the present
study (domain 2, RLS at nighttime) (Table 7).
A strong association (rS > 0.60) was found between the change
captured by the IRLS and the RLS-6 for both groups of treatment.
Previous studies, with a diversity of interventions, have unani-
mously found an evident sensitivity to a change in the RLS-6; overall,
these ﬁndings are in line with the outcomes in the present study
[10,34–36]. Therefore, the intrinsic responsiveness of the RLS-6 can
be deemed satisfactory.
The main limitations of the study were related to the net prev-
alence of women in the sample and the lack of the scale
reproducibility testing. Furthermore, there were no independent in-
terviews comparing the scale with the usual gold standard of
validation, as done for the IRLS validation.
In conclusion, the RLS-6 seems to be an acceptable, reliable,
precise, valid, and responsive instrument for the assessment of RLS
severity in a speciﬁc and pragmatic manner. The RLS-6 is compa-
rable to the IRLS in this regard, and the two scales can be considered
compatible and not contradictory. Each scale provides informa-
tion not captured by the other scale. Indeed, many therapeutic trials
where the IRLS has been used as the primary outcome have applied
both scales because RLS-6 provides detailed additional informa-
tion on RLS symptom severity at different times and under different
circumstances. In addition, the ﬁndings of other studies support the
compatibility of the scales. In a comparative study of the IRLS with
othermeasures of RLS severity, s good correlationwas noted between
the IRLS and the RLS-6 [37]. In this study, both scales showed a
placebo effect around 25%. Future studies with the RLS-6will conﬁrm
the stability of this performance.
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